Baseline characteristics
| Regorafenib (N=100) | |
| Male, n (%) | 58 (58) |
| Age, years | |
| Median (range) | 56.5 (31–78) |
| ≥65 years, n (%) | 22 (22) |
| ECOG PS, n (%) | |
| 0 | 59 (59) |
| 1 | 41 (41) |
| Time from initial diagnosis to treatment assignment | |
| Median (range), months | 33.6 (7.4–138.1) |
| <18 months, n (%) | 11 (11) |
| ≥18 months, n (%) | 89 (89) |
| Time from diagnosis of metastatic disease to treatment assignment | |
| Median (range), months | 29.3 (6.9–138.1) |
| <18 months, n (%) | 17 (17) |
| ≥18 months, n (%) | 83 (83) |
| Primary site of disease, n (%) | |
| Colon | 55 (55) |
| Rectum | 24 (24) |
| Colon and rectum | 21 (21) |
| KRAS status, n (%) | |
| Wild-type | 43 (43) |
| Mutant | 53 (53) |
| Unknown | 4 (4) |
| BRAF status, n (%) | |
| Wild-type | 6 (6) |
| Mutant | 0 |
| Unknown | 94 (94) |
| Brain metastases, n (%) | |
| No | 77 (77) |
| Yes | 2 (2) |
| Unknown | 21 (21) |
| Liver metastases, n (%) | |
| No | 22 (22) |
| Yes | 78 (78) |
ECOG PS, Eastern Cooperative Oncology Group performance status.